PGC1 alpha Antibody | Affinity Biosciences

Product:	PGC1 alpha Antibody
Catalog:	AF5395
Description:	Rabbit polyclonal antibody to PGC1 alpha
Application:	WB IHC
Reactivity:	Human, Mouse, Rat
Prediction:	Pig, Bovine, Horse, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.:	90~140 kD; 91kD(Calculated).
Uniprot:	Q9UBK2
RRID:	AB_2837880

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
100ul	$280	In stock
200ul	$350	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Rabbit

Application:

WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Prediction:

Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(80%)

Clonality:

Polyclonal

Specificity:

PGC1 alpha Antibody detects endogenous levels of total PGC1 alpha.

RRID:

AB_2837880
Cite Format: Affinity Biosciences Cat# AF5395, RRID:AB_2837880.

Conjugate:

Unconjugated.

Purification:

The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

Storage:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

L PGC 1alpha;LEM6;Ligand effect modulator 6;Peroxisome proliferative activated receptor gamma coactivator 1 alpha;Peroxisome proliferative activated receptor gamma coactivator 1;Peroxisome proliferator activated receptor gamma coactivator 1 alpha;Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 3ext;Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4 8a;Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B4;Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5;Peroxisome proliferator activated receptor gamma coactivator 1 alpha transcript variant B5 NT;Peroxisome proliferator-activated receptor gamma coactivator 1-alpha;PGC 1 (alpha);PGC 1 alpha;PGC 1v;PGC-1-alpha;PGC1;PGC1(alpha);PGC1A;PGC1v;PPAR gamma coactivator 1 alpha 3 ligand effect modulator 6;PPAR gamma coactivator 1 alpha;PPAR gamma coactivator 1;PPAR gamma coactivator variant form;PPAR-gamma coactivator 1-alpha;PPARGC 1 alpha;PPARGC-1-alpha;PPARGC1;PPARGC1A;PRGC1_HUMAN;

Immunogens

Immunogen:

Uniprot:

Q9UBK2(PRGC1_HUMAN) >>Visit HPA database.

Gene(ID):

PPARGC1A(10891)

Expression:

Q9UBK2 PRGC1_HUMAN:

Heart, skeletal muscle, liver and kidney. Expressed at lower levels in brain and pancreas and at very low levels in the intestine and white adipose tissue. In skeletal muscle, levels were lower in obese than in lean subjects and fasting induced a 2-fold increase in levels in the skeletal muscle in obese subjects.

Description:

Sequence:

Q9UBK2 PRGC1_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKWCSDQSEIISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGDVTTDNEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLSTQNHANHNHRIRTNPAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLTTNDDPPHTKPTENRNSSRDKCTSKKKSHTQSQSQHLQAKPTTLSLPLTPESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTTPPHKANQDNPFRASPKLKSSCKTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLSKSSVLTGGHEERKTKRPSLRLFGDHDYCQSINSKTEILINISQELQDSRQLENKDVSSDWQGQICSSTDSDQCYLRETLEASKQVSPCSTRKQLQDQEIRAELNKHFGHPSQAVFDDEADKTGELRDSDFSNEQFSKLPMFINSGLAMDGLFDDSEDESDKLSYPWDGTQSYSLFNVSPSCSSFNSPCRDSVSPPKSLFSQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSHYRHRTHRNSPLYVRSRSRSPYSRRPRYDSYEEYQHERLKREEYRREYEKRESERAKQRERQRQKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEECTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFELYFCGRKQFFKSNYADLDSNSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Pig

100

Horse

100

Bovine

100

Dog

100

Chicken

100

Rabbit

100

Xenopus

Sheep

Zebrafish

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9UBK2 As Substrate

Q9UBK2

Site	PTM Type	Enzyme	Source
T178	Phosphorylation	Q13131 (PRKAA1)	Uniprot
S208	Phosphorylation		Uniprot
S246	Phosphorylation		Uniprot
T263	Phosphorylation	Q16539 (MAPK14)	Uniprot
S266	Phosphorylation	Q16539 (MAPK14)	Uniprot
S273	Phosphorylation		Uniprot
K278	Acetylation		Uniprot
S285	Phosphorylation		Uniprot
T295	Phosphorylation		Uniprot
T299	Phosphorylation	Q16539 (MAPK14)	Uniprot
S313	Phosphorylation		Uniprot
K347	Acetylation		Uniprot
K360	Acetylation		Uniprot
K360	Ubiquitination		Uniprot
S416	Phosphorylation		Uniprot
S417	Phosphorylation		Uniprot
K442	Ubiquitination		Uniprot
K464	Ubiquitination		Uniprot
K480	Ubiquitination		Uniprot
S539	Phosphorylation		Uniprot
S571	Phosphorylation	P31751 (AKT2) , P31749 (AKT1)	Uniprot
S616	Phosphorylation		Uniprot
Y634	Phosphorylation		Uniprot
S636	Phosphorylation		Uniprot
Y717	Phosphorylation		Uniprot
T721	Phosphorylation		Uniprot
Y722	Phosphorylation		Uniprot
K758	Ubiquitination		Uniprot
S768	Phosphorylation		Uniprot
K777	Ubiquitination		Uniprot
K779	Ubiquitination		Uniprot
S782	Phosphorylation		Uniprot
S787	Phosphorylation		Uniprot
K790	Ubiquitination		Uniprot

Research Backgrounds

Q9UBK2_PRGC1_HUMAN

Function:

Transcriptional coactivator for steroid receptors and nuclear receptors. Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter. Can regulate key mitochondrial genes that contribute to the program of adaptive thermogenesis. Plays an essential role in metabolic reprogramming in response to dietary availability through coordination of the expression of a wide array of genes involved in glucose and fatty acid metabolism. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner. Also involved in the integration of the circadian rhythms and energy metabolism. Required for oscillatory expression of clock genes, such as ARNTL/BMAL1 and NR1D1, through the coactivation of RORA and RORC, and metabolic genes, such as PDK4 and PEPCK.

PTMs:

Phosphorylation by AMPK in skeletal muscle increases activation of its own promoter. Phosphorylated by CLK2.

Heavily acetylated by GCN5 and biologically inactive under conditions of high nutrients. Deacetylated by SIRT1 in low nutrients/high NAD conditions.

Ubiquitinated. Ubiquitination by RNF34 induces proteasomal degradation.

Subcellular Location:

Nucleus. Nucleus>PML body.

Nucleus.

Cytoplasm. Nucleus.

Nucleus. Nucleus>PML body.

Nucleus.

Tissue Specificity:

Subunit Structure:

Homooligomer. Interacts with MYBBP1A; inhibits MYBBP1A transcriptional activation (By similarity). Interacts with PRDM16, LPIN1 and PML (By similarity). Interacts (via LXXLL motif) with RORA and RORC (via AF-2 motif); activates RORA and RORC transcriptional activation (By similarity). Interacts with LRPPRC. Interacts with RNF34 (via RING-type zinc finger).

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway. (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Neurodegenerative diseases > Huntington's disease.

· Organismal Systems > Aging > Longevity regulating pathway. (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

References

1). Atomically precise gold nanoclusters as ROS-scavenging clusterzymes to treat high-fat diet-induced obesity. Chemical Engineering Journal, 2024 [IF=13.3]

2). Polyoxometalates Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the AMPK Signaling Pathway. International journal of nanomedicine, 2024 (PubMed: 39479173) [IF=8.0]

3). Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway. The journal of headache and pain, 2025 (PubMed: 39871133) [IF=7.3]

4). Zinc ions facilitate metabolic bioenergetic recovery post spinal cord injury by activating microglial mitophagy through the STAT3-FOXO3a-SOD2 pathway. Free radical biology & medicine, 2024 (PubMed: 39613048) [IF=7.1]

5). Resveratrol and its derivative pterostilbene attenuate oxidative stress-induced intestinal injury by improving mitochondrial redox homeostasis and function via SIRT1 signaling. Free radical biology & medicine, 2021 (PubMed: 34648904) [IF=7.1]

6). Thiamine Supplementation Alleviates Lipopolysaccharide-Triggered Adaptive Inflammatory Response and Modulates Energy State via Suppression of NFκB/p38 MAPK/AMPK Signaling in Rumen Epithelial Cells of Goats. Antioxidants, 2022 (PubMed: 36290775) [IF=7.0]

Application: WB Species: Goat Sample: RECs

Figure 6 Thiamine (THI) supplementation modulates energy metabolism disturbance induced by lipopolysaccharide (LPS) in RECs. (A) ATP content for different treatments. (B) The expression of AMPKα1, AMPKα2, SIRT1, and PGC1α genes with different treatments. (C) Representative Western blots for AMPKα, phosphorylated AMPKα (p-AMPKα), SIRT1, and PGC1α protein levels with different treatments. (D–G) Immunoblotting and measurement of intensity. Protein levels were normalized to the respective abundance of β-actin. Data are presented as means ± SEM (standard error of the mean), n = 3/group (results representative of at least three independent experiments); CON group, no added LPS or THI; THI group, 5 μg/mL THI; LPS group, 5 μg/mL LPS; LPTH group, 5 μg/mL THI and 5 μg/mL LPS. * denotes p < 0.05, significant difference.

7). Maternal organic selenium supplementation during gestation enhances muscle fiber area and muscle fiber maturation of offspring in porcine model. Journal of Animal Science and Biotechnology, 2022 (PubMed: 36329544) [IF=7.0]

Application: WB Species: piglets Sample:

Fig. 3 Effect of maternal HMSeBA supplementation during gestation on the expression of muscle fiber type-related genes in the LD muscle of offspring. A The expression of muscle fiber type-related genes in newborn piglets (n = 10). B The percentage of muscle fiber type in newborn piglets (n = 10). C The protein levels of slow MyHC, fast MyHC and PGC-1α in newborn piglets. D Quantification for proteins of newborn piglets. E The expression of muscle fiber type-related genes in weaned piglets (n = 6). F The percentage of muscle fiber type in weaned piglets (n = 6). G The expression of slow MyHC, fast MyHC and PGC-1α proteins in weaned piglets. H Quantification for proteins of weaned piglets. MyHC I, myosin heavy chain type1; MyHC IIa, myosin heavy chain type 2a; MyHC IIb, myosin heavy chain type 2b; MyHC IIx, myosin heavy chain type 2x; PGC-1a, peroxisome proliferator-activated receptor gamma coactivator-1 alpha; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Data are presented as means ± SE. a,b,cP

8). Targeting PARK7 Improves Acetaminophen-Induced Acute Liver Injury by Orchestrating Mitochondrial Quality Control and Metabolic Reprogramming. Antioxidants (Basel, Switzerland), 2022 (PubMed: 36358500) [IF=7.0]

Application: WB Species: Human Sample: L02 cells

Figure 6. Changes in mitochondrial-related indexes after PARK7 silencing. (A) Changes in mitochondrial synthesis proteins in APAP-treated L02 cells with and without PARK7 silencing and statistical analysis, N = 3. * p < 0.05 vs. ShNC group, ** p < 0.01 vs. ShNC group, # p < 0.05vs. ShNC+APAP group, ## p < 0.01 vs. ShNC+APAP group. (B) WB and statistical analysis of the mitochondrial synthetic proteins PGC-1α, NRF1 and TFAM in the liver tissue of mice with or without APAP intervention with PARK7 knockdown, N = 3, * p < 0.05 vs. WT group, ** p < 0.01 vs. WT group, ## p < 0.01 vs. WT+APAP group. (C,D) Changes in mitochondrial respiratory function and glycolytic function under APAP intervention with or without PARK7 silencing, N = 3. * p < 0.05 vs. shNC group, ** p < 0.01 vs. shNC group, # p < 0.05 vs. shNC+APAP group, ## p < 0.01 vs. shNC+APAP group.

9). Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38879892) [IF=6.9]

10). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=6.9]

Application: WB Species: Human Sample: L02 cell

Fig. 6. β-PAE promotes the expression of hepatic lipid oxidation-related proteins and genes in HFD-fed rats. (A–G) Western blot analysis on the expression of SIRT1, PGC-1α, PPARα, FGF21, CPT-1a and ACOX1; (H–K) The mRNA expression of SIRT1, PPARα, CPT-1a and ACOX1. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

PGC1 alpha Antibody - #AF5395